Advertisement

Advertisement

Breast Cancer

Skipping Adjuvant Radiotherapy May Not Impact Risk of Recurrence or Progression in Patients With Low-Risk DCIS

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable 5-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the 2023 San...

Breast Cancer
Genomics/Genetics

Potentially Targetable Fusion RNAs May Be More Common in Metastatic Breast Cancer Than Previously Realized

Comprehensive profiling of fusion RNAs present in a large cohort of metastatic breast tumors revealed unique fusion mutations that may be therapeutically targetable, according to results presented at the 2023 San Antonio Breast Cancer Symposium (Abstract GS03-09). Fusion mutations occur when a...

Breast Cancer

Recipients of 2023 Susan G. Komen Breast Cancer Awards Honored

Susan G. Komen presented its 2023 Breast Cancer Awards to four physician-scientists and one research advocate for their contributions to advancing breast cancer discoveries and improving patient outcomes. The five recipients were recognized at the Susan G. Komen Breast Cancer Awards event in San...

Breast Cancer
Genomics/Genetics

Genetic Characteristics of HER2-Low Advanced Breast Cancers May Guide Treatment Selection

Researchers have revealed significant differences in the genetic characteristics of HER2-low advanced breast cancers, which may lead to the development of novel therapeutics for patients, according to recent findings presented by Kahn et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...

Breast Cancer
Supportive Care

Using Estrogen Levels to Predict Who May Benefit From Preventive Treatment With Anastrozole

Investigators have found that estrogen levels measured through blood tests may be predictive of which individuals at high risk of breast cancer will benefit from aromatase inhibitors, according to a recent study presented by Cuzick et al at the 2023 San Antonio Breast Cancer Symposium (Abstract...

breast cancer

Amy Tiersten, MD, on Metastatic Breast Cancer: A Possible Chemotherapy-Free Front-Line Regimen

Amy Tiersten, MD, of the Icahn School of Medicine at Mount Sinai and Tisch Cancer Institute, discusses findings from the ASPIRE trial, which showed the combination of anastrozole, palbociclib, trastuzumab, and pertuzumab in the front-line setting was well tolerated and effective, with a clinical benefit rate of 97% in patients with previously untreated hormone receptor–positive, HER2-positive metastatic breast cancer (Abstract RF02-01).

breast cancer

Sara A. Hurvitz, MD, on Metastatic Breast Cancer: New Data on Tucatinib and Trastuzumab Emtansine

Sara A. Hurvitz, MD, of Fred Hutchinson Cancer Research Center, University of Washington, discusses phase III findings of the HER2CLIMB-02 study, which showed the combination of tucatinib and trastuzumab emtansine improved progression-free survival in patients with previously treated, HER2-positive, locally advanced or metastatic breast cancer (including those with brain metastases) (Abstract GS01-10).

Breast Cancer

Younger Postmenopausal Patients With Early-Stage Breast Cancer May Be Able to Safely Omit Adjuvant Radiotherapy

Almost all postmenopausal patients aged 50 to 69 with stage I hormone receptor–positive breast cancer and low scores on a common genetic test who opted out of adjuvant radiotherapy were disease-free 5 years after surgery, according to results from the IDEA clinical trial presented at the 2023 San...

Breast Cancer
Supportive Care

Patients With HR-Positive Breast Cancer May Use Fertility Preservation and Assisted Reproductive Technologies Without Increased Risk of Recurrence

Using fertility preservation and/or assisted reproductive technologies (ART) did not adversely impact 3-year cancer recurrence rates among patients with hormone receptor–positive breast cancer who paused endocrine therapy to become pregnant, according to results from the POSITIVE trial presented at ...

Breast Cancer
Supportive Care

Exercise May Boost Quality of Life for Patients With Metastatic Breast Cancer

Patients with metastatic breast cancer who took part in a 9-month structured exercise program reported less fatigue and an improved quality of life compared to those who did not participate in the exercise program, according to results from the PREFERABLE-EFFECT trial presented at the 2023 San...

Breast Cancer

Novel Targeted Therapies May Benefit Patients With Metastatic Hormone Receptor–Positive/HER2-Negative Breast Cancer

Two studies led by researchers at The University of Texas MD Anderson Cancer Center demonstrated clinical benefit from novel targeted therapies, which may offer new treatment options for patients with metastatic hormone receptor–positive/HER2-negative breast cancer. The data were shared in oral...

Breast Cancer
Issues in Oncology

Risk Model May Accurately Predict Aromatase Inhibitor Nonadherence

A novel risk model may be effective at using baseline sociodemographic and financial measures to predict the risk of long-term aromatase inhibitor nonadherence among patients with breast cancer, according to new findings presented by Hershman et al at the 2023 San Antonio Breast Cancer Symposium...

Breast Cancer
Supportive Care

Novel Selective Biomarker Tool May Help Select Effective Targeted Therapies in Patients With Metastatic Breast Cancer

A novel selective biomarker tool (Troplex) may help select which antibody-drug conjugate therapy could be most effective in patients with metastatic breast cancer, according to findings presented by Robbins et al at the 2023 San Antonio Breast Cancer Symposium (Abstract PO3-13-11). Background...

Breast Cancer

Study Finds Link Between T-Cell Diversity in Peripheral Blood, Patient Age, and Stage of Breast Cancer Development

A large cohort study of peripheral blood T-cell receptor (TCR) clonotype diversity in patients with breast cancer diagnosed with either ductal carcinoma in situ or de novo stage IV disease has found that the diversity of T cells is associated with age and intratumor immune status and might be...

Breast Cancer

Tucatinib Plus T-DM1 May Benefit Patients With Advanced or Metastatic HER2-Positive Breast Cancer

A combination of two HER2-targeted drugs—tucatinib and ado-trastuzumab emtansine (T-DM1), extended progression-free survival among patients with unresectable, locally advanced, or metastatic HER2-positive breast cancer compared with T-DM1 alone, according to results from the HER2CLIMB-02 trial...

Breast Cancer

Neoadjuvant Chemotherapy May Help Some Patients With Breast Cancer Skip Regional Nodal Irradiation

For patients whose breast cancer converted from lymph node–positive to lymph node–negative disease after neoadjuvant chemotherapy, skipping adjuvant regional nodal irradiation did not increase the risk of disease recurrence or death 5 years after surgery, according to results from the NRG...

Breast Cancer
Issues in Oncology

Regular Screening Mammograms May Significantly Reduce Breast Cancer Mortality, Swedish Study Shows

Patients who regularly attend screening mammograms may have a reduced risk of breast cancer mortality, according to recent findings presented by Smith et al at the Radiological Society of North America (RSNA) 2023 Scientific Assembly and Annual Meeting (Abstract R1-SSBR10-4). Background Early...

Breast Cancer

TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer

The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...

Breast Cancer

Incidence of Breast Cancer After False-Positive Mammography

In a Swedish study reported in JAMA Oncology, Mao et al found that women with a false-positive mammography result were more likely to be subsequently diagnosed with breast cancer compared to women with no false-positive result. Study Details The study involved data from 45,213 women who received a...

Breast Cancer
Issues in Oncology

Urban Environmental Exposures and Incidence of Breast Cancer

Investigators have uncovered that North Carolina’s urban counties may have higher overall incidences of breast cancer than its rural counties, especially at early stages at diagnosis, according to a recent study published by Gearhart-Serna et al in Scientific Reports. These findings may serve as a...

Breast Cancer

From a Small Town in the Rust Belt, Dennis J. Slamon, MD, PhD, Plays a Big Role in Changing the Face of Breast Cancer Treatment

In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with Dennis J. Slamon, MD, PhD, one of the principals in the discovery and development of trastuzumab—the first monoclonal antibody used against an oncogene that altered our entire approach...

Breast Cancer

Axillary Soft-Tissue Involvement in Lymph Node–Positive Breast Cancer

In a single-institution retrospective analysis reported in the Journal of Clinical Oncology, Naoum et al found that pathologic exploration of axillary soft tissue in patients with lymph node–positive breast cancer is a critical element in predicting disease outcome and in determining axillary...

Breast Cancer

Hypofractionation Shows Comparable Results to Conventional Postmastectomy Radiation Therapy, With Added Benefits

In a major development in the treatment of breast cancer, short-course, or hypofractionated, radiation therapy has demonstrated comparable outcomes to conventional postmastectomy radiation therapy while reducing treatment breaks and financial toxicity, according to data presented at the 2023...

Breast Cancer

Early Breast Cancer: Effect of Radiotherapy to Regional Nodes

As reported in The Lancet by the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG), an individual patient meta-analysis has shown that more recent—but not older—trials of regional lymph node radiotherapy vs no radiotherapy in patients with early breast cancer showed benefits of...

Breast Cancer

Overall Survival With CTC Count–Driven Treatment in Advanced Breast Cancer

As reported in the Journal of Clinical Oncology by François-Clément Bidard, MD, PhD, and colleagues, the French phase III STIC CTC trial showed a nonsignificant overall survival benefit with a circulating tumor cell (CTC) count–driven approach to therapy vs physician’s choice in the first-line...

Breast Cancer

Partial-Breast Irradiation in Patients With Early-Stage Invasive Breast Cancer or DCIS

The American Society for Radiation Oncology (ASTRO) issued recommendations for patient-centered strategies for performing partial-breast irradiation in patients with early-stage invasive breast cancer or ductal carcinoma in situ (DCIS). The new clinical guidelines were published by Shaitelman et al ...

Breast Cancer

FDA Approves Capivasertib With Fulvestrant for Breast Cancer

On November 16, 2023, the U.S. Food and Drug Administration (FDA) approved capivasertib (Truqap) with fulvestrant for adult patients with hormone receptor–positive, HER2-negative locally advanced or metastatic breast cancer with one or more PIK3CA/AKT1/PTEN alterations, as detected by an...

Breast Cancer

TROPION-Breast01 and DESTINY-Breast04: Antibody-Drug Conjugates of Benefit in Patients With Metastatic Breast Cancer

The TROP-2–directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) significantly improved progression-free survival over standard chemotherapy in the TROPION-Breast01 trial involving patients with previously treated, hormone receptor–positive, HER2-negative, unresectable and/or...

Breast Cancer
Issues in Oncology

Vitamin D Supplements May Help Reduce Chemotherapy-Induced Peripheral Neuropathy

Investigators have found that patients with breast cancer who have insufficient levels of vitamin D prior to initiating treatment with paclitaxel may be more likely to experience peripheral neuropathy, according to a recent study published by Chen et al in JNCCN–Journal of the National...

breast cancer

Nadia Harbeck, MD, PhD, on High-Risk Early Breast Cancer: Overall Survival Data on Abemaciclib Plus Endocrine Therapy

Nadia Harbeck, MD, PhD, of Munich’s LMU University Hospital and the Ludwig Maximilian University, discusses an interim analysis of the monarchE trial on adjuvant abemaciclib plus endocrine therapy for patients with hormone receptor–positive, HER2-negative, high-risk early breast cancer. The data showed this regimen continued to reduce the risk of developing invasive and distant disease recurrence well beyond the completion of treatment. The improvement at 5 years is consistent with a carryover effect and further supports the use of the CDK4/6 inhibitor abemaciclib in this population (Abstract LBA17).

breast cancer
immunotherapy

Peter Schmid, MD, PhD, on Triple-Negative Breast Cancer: Updated Results on Pembrolizumab Plus Chemotherapy

Peter Schmid, MD, PhD, of Queen Mary University of London, discusses phase III findings from the KEYNOTE-522 study, which showed neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab continues to improve event-free survival compared with neoadjuvant chemotherapy alone in patients with early-stage triple-negative breast cancer, regardless of pathologic complete response (Abstract LBA18).

Breast Cancer
Issues in Oncology

Secondary PIK3CA Mutations, Drug Resistance, and Novel PI3K Alpha Inhibitors in Breast Cancer

Researchers have discovered that resistance to PI3K-alpha inhibitors and reduced drug binding in patients with breast cancer may be driven by secondary PIK3CA mutations and so may be effectively treated with a novel class of PI3K-alpha inhibitors designed to bind to different parts of the target,...

Breast Cancer
Colorectal Cancer
Gynecologic Cancers
Issues in Oncology

Insurance Coverage Disruptions May Reduce Rate of Cancer Screenings

Investigators have found that U.S. adult patients with prior insurance coverage disruptions may be less likely to receive guideline-concordant and past-year cancer screenings compared with those with continuous coverage, according to new findings presented by Shi et al at the 2023 ASCO Quality Care ...

breast cancer

Early Triple-Negative Breast Cancer

This is Part 3 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early triple-negative breast cancer. The patient is a 54-year-old Black female who notices nipple retraction in the left breast. Ultrasound reveals a 3.8-cm mass, and biopsy confirms estrogen receptor 0, progesterone receptor 0, HER2 1+ by IHC, FISH nonamplified, grade 3 disease, with a high Ki-67 of 60%. She undergoes lymph node sampling, which is also positive for invasive ductal carcinoma.   The faculty review neoadjuvant chemotherapy options for patients with node-positive, triple-negative breast cancer, whether PD-L1 status has any impact in the early-stage setting, the importance of genetic testing, and the clinical implications of the KEYNOTE-522 and OlympiA trials.

breast cancer

Early Node-Negative HER2-Positive Breast Cancer

This is Part 2 of Updates in Early-Stage Breast Cancer,, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early node-negative HER2-positive breast cancer. The patient is a 53-year-old White female with a right breast abnormality noted on screening mammogram. The mass is biopsied, revealing a 1.1-cm lesion that is estrogen receptor positive, progesterone receptor negative, HER2 amplified. Due to the small size, she undergoes lumpectomy and is found to have 1.2-cm invasive ductal carcinoma that is HER2-amplified with zero out of two lymph nodes involved.   In the conversation that follows, the faculty discuss the impact of tumor size on adjuvant treatment selection for patients with node-negative HER2-positive breast cancer, which patients are candidates for neoadjuvant HER2-directed therapy, and the clinical implications of the APT and KATHERINE trials.

breast cancer

Early Hormone Receptor–Positive/HER2-Negative Breast Cancer

This is Part 1 of Updates in Early-Stage Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this Roundtable.   In this video, Drs. Erika Hamilton, Michael Danso, and Komal Jhaveri discuss the management of early hormone receptor–positive/HER2-negative breast cancer. The patient is a 42-year-old female who presents with a right breast lump that has been palpable for 2 months. Mammogram reveals a 3-cm abnormality that upon biopsy was determined to be estrogen receptor 100%, progesterone receptor 90%, HER2 0, grade 3 invasive ductal carcinoma. She has no abnormal lymph nodes and an Oncotype recurrence score of 21. Following initial treatment with chemotherapy, she undergoes lumpectomy and is found to have 1.5 cm of high-grade residual carcinoma, one out of three positive lymph nodes, and a 5-mm cancer deposit.   In the conversation that follows, the faculty discuss initial treatment options for this patient, whether recommendations for chemotherapy would change depending on menopausal status, the role of endocrine therapy, and the clinical implications of the monarchE and NATALEE trials.

Breast Cancer
Issues in Oncology

Patient Education Materials on Breast Cancer May Be Difficult to Access

Investigators have discovered that reliable educational materials about breast cancer surgery may be difficult to access and are often presented at much higher reading levels than recommended, according to the findings of two new studies presented by Brennan et al and Satarasinghe et al at the...

Breast Cancer
Thyroid Cancer
Pancreatic Cancer
Issues in Oncology

AI-Based Calculator May Accurately Predict Long-Term Cancer Survival

Researchers have developed a novel artificial intelligence (AI)-based Cancer Survival Calculator for estimating long-term survival in patients with newly diagnosed cancer, according to new findings presented by Janczewski et al at the American College of Surgeons (ACS) Clinical Congress 2023....

Breast Cancer
Survivorship

Novel Strategies for Eliminating Dormant Tumor Cells in Breast Cancer Survivors

Researchers have discovered that it may be possible to detect and treat dormant tumor cells in breast cancer survivors, according to new findings presented by DeMichele et al at the European Society for Medical Oncology (ESMO) Congress 2023 (Abstract 244MO). The results may have offered a...

Breast Cancer

Air Pollution and Breast Cancer Risk: Residential and Workplace Exposure

Women living and working in places with higher levels of fine particle air pollution are more likely to get breast cancer than those living and working in less polluted areas. Results of a study looking at the effects of both residential and workplace exposure to air pollution on breast cancer risk ...

Breast Cancer

Breast Cancer 2022–2023 Almanac

The past year has been an exciting time for breast oncologists and patients with all stages of breast cancer, with new agents approved and long-term results from pivotal trials showing improved survival for patients with metastatic disease. Let’s take a look at some of the highlights in early-stage ...

Breast Cancer

Recent FDA Approvals in Breast Cancer

Over the past year, the U.S. Food and Drug Administration (FDA) granted approval to several novel drugs and expanded indications for older therapeutic agents used in breast cancer. Abemaciclib Plus Endocrine Therapy On March 3, 2023, the FDA expanded the indication for abemaciclib with endocrine...

Breast Cancer

Expert Point of View: Meritxell Bellet Ezquerra, MD, PhD, and Sung-Bae Kim, MD, PhD

The MONARCH 3 study’s invited discussant, Meritxell Bellet Ezquerra, MD, PhD, a senior researcher at the Vall d’Hebron Institute of Oncology in Barcelona, commented: “The second interim analysis for overall survival in MONARCH 31 indicates a positive trend, which was also observed for the subgroup...

Breast Cancer

Overall Survival in Two Monarch Trials of Abemaciclib in Advanced Breast Cancer

Overall survival results from two trials of abemaciclib in advanced breast cancer were reported at the European Society for Medical Oncology (ESMO) Congress 2022. Both MONARCH 3 and monarcHER previously met their primary endpoints of progression-free survival. The current results for overall...

Breast Cancer

Can Younger Women With Hormone Receptor–Positive Breast Cancer Safely Pause Endocrine Therapy to Pursue Pregnancy?

Preserving fertility is a driving concern for many young women with breast cancer. Many of these women have hormone receptor–positive breast cancer and are treated with adjuvant endocrine therapy for 5 to 10 years, which is known to compromise fertility. Younger women who may want to take a break...

Breast Cancer

SOFT Analysis: Breast Cancer Index May Identify Which Patients Need Ovarian Suppression

In an analysis of the SOFT trial, the Breast Cancer Index accurately identified premenopausal women with hormone receptor–positive early breast cancer who may benefit from ovarian function suppression in addition to adjuvant endocrine therapy. The findings were reported by Ruth O’Regan, MD, Chair...

Breast Cancer

Capivasertib Plus Fulvestrant Doubles Progression-Free Survival in Hormone Receptor–Positive, HER2-Negative Advanced Breast Cancer

The combination of capivasertib, an AKT pathway inhibitor, plus fulvestrant, an estrogen receptor antagonist, significantly improved progression-free survival compared with fulvestrant alone in patients with hormone receptor–positive, HER2-negative advanced breast cancer, according to results of...

Breast Cancer

Palbociclib/Fulvestrant Does Not Improve Progression-Free Survival After Progression on a CDK4/6 Inhibitor in Metastatic Breast Cancer

The combination of palbociclib and fulvestrant did not prolong progression-free survival compared to fulvestrant alone in patients with hormone receptor–positive/HER2-negative metastatic breast cancer who had disease progression on prior treatment with a CDK4/6 inhibitor and endocrine therapy,...

Breast Cancer
Immunotherapy

Expert Point of View: Neelima Vidula, MD

Commenting on the DESTINY-Breast03 presentation at the 2022 San Antonio Breast Cancer Symposium, Neelima Vidula, MD, a medical oncologist at Mass General Cancer Center, said: “The results highlight the important survival differences of T-DXd [fam-trastuzumab deruxtecan-nxki] compared to T-DM1...

Breast Cancer
Immunotherapy

T-DXd Confirmed as Preferred Second-Line Therapy for Metastatic HER2-Positive Breast Cancer

The antibody-drug conjugate fam-trastuzumab deruxtecan-nxki (T-DXd) proved to be superior to the antibody-drug conjugate ado-trastuzumab emtansine (T-DM1), significantly improving progression-free survival and overall survival, in women with unresectable or metastatic HER2-positive breast cancer as ...

Advertisement

Advertisement

Advertisement